Summary:
In overweight or obese adults with type 2 diabetes (T2DM) and non-alcoholic fatty liver disease (NAFLD), combination therapy of semaglutide (GLP-1 receptor agonist) and empagliflozin (SGLT-2 inhibitor) administered over 52 weeks significantly improved liver fat reduction (as assessed by controlled attenuation parameter), liver enzyme levels, blood glucose control, and lipid profiles compared to monotherapy using either semaglutide or empagliflozin individually for the same duration, with safety and tolerability analyses supporting the use of the combination treatment.
| PICO | Description |
|---|---|
| Population | Overweight or obese adults with type 2 diabetes (T2DM) and non-alcoholic fatty liver disease (NAFLD). |
| Intervention | Combination therapy of semaglutide (GLP-1 receptor agonist) and empagliflozin (SGLT-2 inhibitor) administered over 52 weeks. |
| Comparison | Monotherapy using either semaglutide or empagliflozin individually for the same duration. |
| Outcome | The combination therapy showed significant improvements in liver fat reduction (as assessed by controlled attenuation parameter), liver enzyme levels, blood glucose control, and lipid profiles compared to monotherapy. Safety and tolerability analyses supported the use of the combination treatment. |
Source: Yu-Hao Lin, et al. “Semaglutide combined with empagliflozin vs. monotherapy for non-alcoholic fatty liver disease in type 2 diabetes: Study protocol for a randomized clinical trial.” PLoS One, 2024. Read article here.
